Menu
Recruiting NCT07356323

A Prospective, Single-arm, Trial to Determine Contamination Rates When Using an Antibacterial Incise Drape During Orthopedic Surgery

No phase Interventional Arthroplasty Replacement, Knee Arthroplasty Total Hip Replacement

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: 3M™ Ioban™ CHG Chlorhexidine Gluconate Incise Drape (2% w/w CHG).
Who it may be relevant to
Registry conditions: Arthroplasty Replacement, Knee, Arthroplasty Total Hip Replacement. Basic parameters: from 22 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The goal of this clinical study is to generate data on the intended use of a chlorhexidine gluconate (CHG)-impregnated antimicrobial incise drape. The study includes subjects undergoing primary hip or knee arthroplasty procedures. The study evaluates the intraoperative performance and safety of the incise drape during surgery, including assessment of contamination and operative characteristics. Participants will have a CHG-impregnated antimicrobial incise drape applied during their surgical procedure. During surgery, samples will be collected from the operative site to assess potential bacterial contamination.

Detailed description

This is a prospective, single-arm clinical study conducted in the United States in subjects undergoing primary hip or knee arthroplasty. The study evaluates the intraoperative performance and safety of a chlorhexidine gluconate (CHG)-impregnated antimicrobial incise drape used during lower extremity orthopedic surgery.

Safety and intraoperative performance outcomes will be assessed throughout the study.

Interventions

  • Device 3M™ Ioban™ CHG Chlorhexidine Gluconate Incise Drape (2% w/w CHG)
    A CHG-impregnated antimicrobial incise drape applied to the surgical site prior to incision during primary hip or knee arthroplasty.

Primary outcome measures

  • Evaluation of the presence of contamination at the surgical site during the operative procedure. [Time frame: During surgery]

Eligibility criteria

Inclusion criteria

  • Subject is ≥ 22 years of age on the day of surgery.
  • Subject is scheduled to undergo a unilateral primary arthroplasty procedure on a hip or knee.
  • Subject is capable of providing informed consent.
  • Subject is willing and able to return for all visits.

Exclusion criteria

  • Subject is pregnant or lactating prior to surgery.\*

\*Women who have had surgical sterilization by a medically accepted method (e.g., tubal ligation, hysterectomy, or oophorectomy) or are post-menopausal, defined as not having menstruation for > 12 months will not be required to undergo pregnancy testing

  • Subject is scheduled to undergo a lower extremity bilateral arthroplasty procedure.
  • Subject had a previous open knee surgery on the study knee or is scheduled to undergo a revision knee arthroplasty.
  • Subject has had a previous surgery for revision femoral acetabular osteotomy or total hip arthroplasty on the study hip.
  • Subject is scheduled for lower extremity arthroplasty due to trauma.
  • Subject was previously diagnosed with septic arthritis or has a history of infection in the joint.
  • Subject has taken any antibiotics within 4 weeks before surgery.
  • Subject has an allergy or sensitivity to components of the device (e.g., chlorhexidine gluconate or acrylate-based adhesive).
  • Subject is currently enrolled in another trial.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Prevention

Study locations

United States · 2 centers
  • Indiana University Health (IU Health) — Fishers
  • University of Utah Health - Department of Orthopedics — Salt Lake City

Identifiers

NCT: NCT07356323 · EM-05-015132

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗